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Abstract
Lung cancer patients have the highest mortality among patients with solid 
tumors worldwide and their prognosis is strictly stage-associated. However, only 
15–20% of patients are diagnosed in stage I, since these early tumors are frequently 
asymptomatic. Early detection of lung cancer, which allows effective therapeutic 
intervention, is a promising approach to lowering its mortality rate. However, 
conventional diagnostic methods for lung cancer, such as chest X-ray and CT of the 
chest, produce high costs and potentially false-positive results. Thus, the discovery 
of highly sensitive, specific, noninvasive, and cost-effective lung cancer biomarkers 
combined with conventional approaches, such as X-rays, may improve the sensitiv-
ity of lung cancer screening. Herein, we summarize the most recent studies about 
the molecular pathology of lung cancer and discuss the advancements expected in 
the near future, including the potential biomarkers and liquid biopsy approaches 
for the detection of lung cancer in populations at risk of developing this disease.
Keywords: lung cancer, CT, biomarkers, lung cancer screening, liquid biopsy, 
cfDNA, CTCs
1. Introduction
Despite multimodality treatment strategies including surgery, radiotherapy, 
chemotherapy, and targeted therapy, lung cancer is still the first leading cause 
of cancer-related death in the world with the 5-year lung cancer survival rate 
remaining as low as 15% [1–3]. The most common histologies are summarized as 
non-small cell lung cancer (NSCLC) and account for 80–85% of newly diagnosed 
cases. Surgery is the standard of care for functionally operable early stage NSCLC 
and resectable stage IIIA disease and possesses a potential for cure. However, only 
20% of NSCLC are resectable at diagnosis [4]. Histology and cytology of thoracic 
biopsies are currently the gold standard that asserts early diagnosis of lung cancers 
detected by thoracic imagery. Nevertheless this approach is costly and often detects 
false positive nodules that turn out not to be cancers. Therefore, early detection 
approaches—especially directed toward the population at high risk for the develop-
ment of this disease—remain an unmet clinical need. Several studies have been 
performed to define the ideal approach that should be sensitive, specific, reliable, 
and reproducible for early diagnosis of lung cancer or for prediction of the devel-
opment of this disease in subjects at risk. This review summarizes the molecular 
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biology of lung cancer and conventional diagnostic methods currently used, with a 
particular attention on the development of new screening approaches such as liquid 
biopsy to improve the early detection of this disease.
2. The molecular landscape of lung cancer
2.1 Gene mutations
Recent advances in next-generation sequencing (NGS) and other high-
throughput genomic profiling platforms have allowed the examination of the 
breadth of genetic mutations within lung cancer. The most common mutation is 
in the Kirsten rat sarcoma (KRAS) oncogene, occurring in approximately 30% 
of adenocarcinomas (Ade) predominantly in patients with a history of smoking 
[5]. BRAF is mutated in approximately 3% of patients (with half of cases being 
the V660E mutation) [6]. Along with KRAS and BRAF, epidermal growth factor 
receptor (EGFR) mutations were discovered in patients with Ade and small cell 
lung cancer (SCLC) [5]. Moreover, mutations and amplifications in many onco-
genes have been identified, including HER2, MET, as well as fusion oncogenes 
involving anaplastic lymphoma kinase (ALK), neuregulin 1 (NRG1), neurotrophic 
tyrosine kinase receptor type 1 (NTRK1), and RET [7–13]. Microtubule-associated 
protein-like 4 (EML4) and ALK fusion gene is another important driver gene in 
lung cancer, which was discovered by Soda et al. in 2007 [10]. In NSCLC, EML4/
ALK is an aberrant fusion gene that encodes a cytoplasmic chimeric protein with 
constitutive kinase activity. The incidence of EML4/ALK fusion in cohorts of 
patients with NSLCL ranges from 1.6% to as high as 19.3%. Genes such as discoidin 
domain-containing receptor 2 (DDR2); fibroblast growth factor receptor 1, 2, and 
3 (FGFR1, FGFR2, FGFR3); and genes in the phosphatidylinositol 3 kinase (PI3K) 
pathway seem instead to be more commonly mutated in squamous cell carcinoma 
(SCC). Many of these mutations have been validated by preclinical studies as driver 
mutations [14–16]. Aberration in stem cell factor receptor tyrosine kinase (c-KIT), 
PI3K catalytic subunit alpha (PIK3CA), PI3K/AKT/mTOR, phosphatase and tensin 
homolog (PTEN), insulin-like growth factor receptor (IGFR1), and hedgehog 
(Shh) signaling pathways have been identified in lung cancer [7] (Table 1).
2.2 ALDH family proteins
The cancer stem cell model proposes that tumor progression, drug resistance, 
metastasis, and relapse after therapy may be driven by a subset of cells within the 
tumor: the cancer stem cells (CSCs) [17–20]. Recent evidences suggest that like 
other tumors, human lung cancers may also harbor CSC populations. Human 
alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) are the 
principal enzymes responsible for ethanol metabolism and have heterogeneous 
tissue distribution. Isoenzymes of ADH participate in bioamine, prostaglandin, and 
retinoid acid metabolism [21]. The second enzyme ALDH belongs to a large family 
of intracellular enzymes that participate in cellular detoxification, differentiation, 
and drug resistance through the oxidation of endogenous and exogenous aldehydes 
to carboxylic acids [22]. The ALDH superfamily currently consists of 19 known 
putatively functional genes in 11 families and 4 subfamilies with distinct chromo-
somal locations [23–25]. Several studies have explored the biological significance 
of ALDH in cancers such as head and neck cancer, colon cancer, breast cancer, 
papillary thyroid carcinoma, and specifically lung cancer, where they have provided 
supportive evidence for the association between ALDH activity and lung cancer 
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stem cells [26–32]. ALDH1A1 seems to be co-expressed with other NSCLC stem 
cell markers such as leucine-rich repeat-containing G-protein-coupled receptor 5 
(LGR5) in NSCLC tissues, and their expression is significantly associated with stage 
disease and poor prognosis [33]. It was reported that ALDH1A1-negative expres-
sion in lung cancer patients corresponds to shorter survival compared to those 
with ALDH1A1-positive expression and that ALDH1A1 overexpression was associ-
ated with a favorable outcome. Moreover, high expression of ALDH1A1 mRNA 
was found to be correlated to a better overall survival (OS) in all NSCLC patients 
followed for 20 years. In addition, high expression of ALDH1A1 mRNA was also 
found to be correlated to better OS in Ade patients but not in SCC patients. These 
results strongly support that ALDH1A1 mRNA in NSCLC is associated with better 
prognosis. However, there are other contradictory results indicating that ALDH1 
cytoplasmic expression was associated with poor prognosis in several tumors, such 
as NSCLC [34]. Jiang et al. also showed that ALDH1A1 expression was positively 
correlated with the stage and grade of lung tumors and related to a poor prognosis 
[34]. A recent meta-analysis showed that increased ALDH1A1 expression is associ-
ated with poor OS and disease-free survival in lung cancer patients [35]. Previous 
studies showed that also several other ALDH isoforms are involved in lung cancer as 
ALDH3A1, highly expressed in two types of NSCLC, Ade and SCC, and ALDH3B1 
expression was also found to be upregulated in a high percentage of human tumors, 
particularly in lung cancer [36–38].
3. Lung cancer screening
Cancer screening is promising for malignancies with a stage-dependent prog-
nosis, and it aims to reduce morbidity and mortality through detection of cancer at 
an early stage. In general, the screening programs have to be subjected to a rigor-
ous risk-benefit assessment taking into account the endpoints as cancer-related 
Altered genes Histology Mutation frequency (%) References
KRAS Ade 30 [5]
BRAF NSCLC 3 [6]
EGFR ADC 19 [5]
HER2 Ade 10 11
MET NSCLC 8–10 [6]
FGFR1 SCC 22 [14, 15]
CD74-NRG1 Ade 27 [8]
NTRK1 Ade 3.3 [13]
KIF5B- and CCDC6-RET Ade 0.9 [13]
EML4/ALK NSCLC 6.7 [10]
DDR2 SCC 4 [16]
c-KIT SCLC, NSCLC 30–40 (SCLC), 40 (NSCLC) [7]
PIK3CA SCC 70 [7]
PTEN SCLC 70 [7]
IGFR1 NSCLC 29.2 [80]
Table 1. 
Recurrent somatic genetic alterations detected in lung cancer.
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mortality, overall mortality, morbidity, patient-reported outcome, and costs. All the 
screening programs need a transparent system of quality assurance.
3.1 Low-dose computed tomography
Several studies on lung cancer screening were conducted mainly by using chest 
X-rays (CXR) for imaging alongside sputum cytology. The National Lung Screening 
Trial (NLST) enrolled 53,000 individuals aged 55–74 years with a 30-pack-year 
smoking history, and participants were randomly assigned to radiography or 
low-dose CT. The low-dose CT group had a 20% reduction in lung cancer mortal-
ity and a 6–7% reduction in all-cause mortality [39]. The International Early Lung 
Cancer Action Program (I-ELCAP) analyzed retrospectively the outcomes of more 
than 21,000 patients after the completion of the NLST. Different size threshold 
for nodule diameters resulted in different cancer diagnosis rates. Increasing the 
threshold from 5 to 0 mm to 6–0, 7–0, 8–0, or 9–0 mm also changed the frequencies 
of positive results [40]. With respect to North American, European studies per-
formed on a smaller number of individuals at risk of lung cancer showed somewhat 
inconsistent and less significant results [41–43]. Although these studies showed 
an improved stage distribution in favor of earlier stages, better resectability of the 
tumors, and also improved survival, an effect on overall mortality could not be 
demonstrated [39, 44, 45]. Aside from the morbidity and mortality that is not justi-
fied within this context, the expenses turn out to be substantial, as thoracic imagery 
can be repeated, leading also to debated benefit risks. Despite the progress made 
in imagery, which allowed the detection of nodules less than 3–4 mm and even the 
definition of the malignant or benign features, currently cancerous lesions less than 
1 mm cannot be detected by imagery [46]. A major drawback of low-dose CT is the 
large number of false-positive tests and the diagnosis of indolent tumors which in 
turn lead to an increased morbidity from unnecessary surgical treatment [47–50]. 
Thus, even if the imagery can allow early stage asymptomatic and operable lung 
cancer detection, these approaches are not satisfactory because of high cost, high 
risk of radiation exposure, and poor sensitivity and specificity.
3.2 Biomarkers for lung cancer detection
The discovery of cancer biomarkers, specific molecules that help to distinguish 
between normal and cancerous conditions, may potentially be used to develop a 
more effective diagnostic tool for cancer. Body fluids (blood, pleural effusion, etc.) 
that are in contact with tumors are enriched with proteins shed from cancer cells. 
Proteins secreted from cancer cells could enter the blood circulation and have the 
potential to be monitored in plasma/serum. Carcinoembryonic antigen (CEA) is an 
oncofetal protein not typically expressed in adult tissues. In lung cancer the CEA 
levels in blood are elevated and are inversely correlated with the response to cancer 
therapy. Therefore, this marker is used for the detection of cancer recurrence and 
the prediction of a poor survival rate. CYFRA-21-1 is a fragment of cytokeratin 
19 that is typically associated with epithelial cell cancers including NSCLC. This 
marker is correlated with disease response and the prognosis of cancer but cannot 
be used to identify cancer patients from patients with respiratory diseases. The 
sensitivity of CYFRA 21-1 for NSCLC ranges between 23 and 70% [51, 52]. Neuron-
specific enolase (NSE) is a glycolysis enzyme produced in neuronal cells and cells 
with neuroendocrine differentiation. SCLC is of neuroendocrine origin, and 
therefore NSE is found to be elevated in patients’ blood [53]. Tumor M2-pyruvate 
kinase (PKM2) is a dimeric form of the pyruvate kinase isoenzyme type M2 that is 
increased in various cancers [52, 54]. C-reactive protein (CRP) is an acute-phase 
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protein, the levels of which rise in response to inflammatory conditions such as lung 
cancer. However, recent studies suggested that CRP could be used as a prognostic 
biomarker of lung cancer and angiogenesis [55]. Serological markers such as CEA, 
NSE, and CYFRA 21-1 are used for the monitoring of treatment effects in lung 
cancer, but their diagnostic value as screening biomarkers is still being debated 
[56, 57]. To date, no useful marker has been identified for the screening of asymp-
tomatic patients. Ideally, a biomarker should have a sensitivity and specificity of 
100%, a goal that is almost never achieved. One strategy potentially increasing both 
parameters is to combine several biomarkers into a screening marker panel. Several 
studies with smaller panels encompassing few markers provided first evidence that 
simultaneous analysis of several antigens have a higher potential for separating 
patients with lung cancer from controls [56]. Combined with other noninvasive 
methods, this may allow for further refinement of lung cancer screening [58].
4. Future perspectives
4.1 New potential lung cancer biomarkers
Proteomics studies showed new lung cancer biomarkers that can be tested in the 
blood (Table 2). Plasma kallikrein (KLKB1) enzyme cleaves Lys-Arg and Arg-Ser 
bonds in kininogen to release bradykinin and has functions related to blood coagula-
tion. Studies evidenced how serum levels of its fragmentation form were increased 
in lung cancer samples compared with normal control sera [59, 60]. Serum amyloid 
A (SAA) proteins are a family of apolipoproteins associated with the high-density 
lipoprotein (HDL) complex that are secreted during the acute phase of inflamma-
tion. In particular, isoforms SAA1/2 were detected in Ade patients’ sera but not in 
healthy donors’ sera using liquid chromatography/mass spectrometry (LC-MS/
MS). This protein was also detected in tissue [59, 61]. Haptoglobin (Hp) is a free 
hemoglobin-binding glycoprotein that inhibits the oxidative stress of hemoglobin 
and assists in hemoglobin uptake. It is a tetramer constituted by two α and two β 
chains. High levels of Hp have been reported in various cancer types including lung 
cancer. Proteomics analysis showed Hp β chain peptide levels to be threefold higher 
in lung cancer patients’ sera with respect to control subjects [59, 62]. Complement 
component 9 (C9) protein, a terminal constituent of the membrane attack complex, 
plays a role in the immune response by forming plasma membrane pores. This 
protein was identified in sera of patients with SCC by glycoproteomics approaches. 
Its protein levels were significantly higher in SCC patients than those in healthy 
donors and in patients with other cancer types [59, 63]. Insulin-like growth factor-
binding protein-2 (IGFBP-2), member of the insulin-like growth factor-binding 
protein family, inhibits IGF-mediated growth and development rates. Increased 
levels of IGFBP-2 have been found in solid tumors and in blood from patients with 
glioma and colorectal, prostate, and breast cancers above all at advanced stage 
disease. Recently circulating anti-IGFBP-2 autoantibodies and IGFBP-2 combined 
markers showed increased diagnostic sensitivity and specificity for lung cancer 
with respect to IGFBP-2 alone [64]. Peroxiredoxin 1 (PRX1) and peroxiredoxin 2 
belong to a family of ubiquitous multifunctional antioxidant proteins. The main 
function of PRX1 is to eliminate peroxides generated during metabolism. PRX1 is 
also involved in the inhibition of oncogenes, and its protein levels were found to 
be higher in human cancer cells and tissues. Recently, PRX1 was also identified in 
lung cancer patients’ plasma by mass spectrometry-based screening technology. 
Plasma PRX1 levels were increased in patients with lung cancer and also in subjects 
exposed to asbestos [65]. Endoglin (CD105) is a major cell membrane glycoprotein 
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of the vascular endothelium. The main function of CD105 is to help the binding 
of endothelial cells to integrins and other receptors promoting angiogenesis by the 
activation of endothelial cells. CD105 overexpression was found in the endothelium 
of vessels in human solid tumors and is closely associated with a poor prognosis and 
the presence of metastases. Moreover levels of soluble CD105 (s-endoglin), formed 
by the cleavage of ectodomain of membrane receptors, were higher in patients 
with various types of cancer compared to normal counterparts, and its levels were 
also associated to metastases. In NSCLC s-endoglin serum levels were significantly 
decreased in postoperation patients, confirming its potential use for monitoring and 
prognosis of lung cancer [59, 66]. Progesterone receptor membrane component 1 
(Pgrmc1) is a cytochrome b5-related protein induced by carcinogens. In fact, Pgrmc1 
levels are elevated in spontaneous ovarian, breast, and lung cancers. Pgrmc1 is 
known to localize at the endoplasmic reticulum, and it was identified as a sigma-2 
receptor, which is induced in cancers. Recently, Pgrmc1 showed also the potential 
to be a serum biomarker for lung cancer. It was shown that Pgrmc1 is localized in 
secretory vesicles and is secreted by lung cancer cells. Moreover, Pgrmc1 levels in the 
plasma and in the exosome fractions of plasma were significantly increased in lung 
cancer patients [59, 67]. Pro-gastrin-releasing peptide (proGRP, residue 31–98) is 
a more stable biochemical precursor of gastrin-releasing peptide (GRP), which is 
specifically produced by the neuroendocrine origin of SCLC cells. In a recent report, 
proGRP levels were increased in SCLC patients with respect to patients with other 






SAA Ade MRM, 
LC-MS/MS
[59, 61]
Hp β chain peptide Lung 
cancer
ELISA, WB [59, 62]

























Cleaved uPAR NSCLC ELISA [71]
ADAM28 NSCLC ELISA [72]
ALDH1A1 NSCLC ELISA [72]
Table 2. 
New potential lung cancer serological biomarkers.
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types of lung cancer; its levels are also associated with the progression of the disease 
[59, 68]. Ciz1 is a nuclear matrix protein which promotes the initiation of mamma-
lian DNA replication. Recently, variant Ciz1 (24 nucleotides from the 3′end of exon 
14 are excluded, leading to in frame deletion of eight amino acids ‘VEEELCKQ’) 
protein levels were significantly increased in the plasma of early stage lung cancer 
patients compared with that from healthy donors and with other respiratory diseases 
suggesting its potential use as a diagnostic lung cancer biomarker. Its sensitivity and 
specificity for stage I NSCLC were 95 and 74%, respectively [59]. MMP-1 is a collage-
nase that cleaves collagen types I, II, III, IV, and X at one site in the helical structure 
and is overexpressed in various cancer cells. High plasma levels of MMP-1 seem to 
be associated with a lower patient survival rate [59, 69]. uPAR is a glycosylphospha-
tidylinositol (GPI)-anchored glycoprotein and cell surface receptor specific to the 
urokinase plasminogen activator (uPA). The uPA-catalyzed cleavage of uPAR is a 
negative feedback loop in which uPA cleaves uPAR leaving the cleaved form of uPAR 
attached to the cell surface. It was shown that serum levels in preoperative NSCLC 
patients are correlated with higher levels of cleaved uPAR and lower survival rate 
[59, 70]. Kuroda et al. showed that ADAM28, a disintegrin and metalloproteinase 
28 overexpressed in NSCLC tissues, was detectable also in serum of patients and 
increases with progress of tumor stage [71]. The sensitivity, false-negative rate, 
and AUC for ADAM28 were even better than those for CEA, suggesting a potential 
use of this test for diagnosis and monitoring of NSCLC. Recently, serum levels of 
ALDH1A1 were shown to be elevated in the sera of patients with NSCLC. Combined 
testing of serum ALDH1A1 and CEA levels significantly increased the screening sen-
sitivity of CEA alone [72]. We provided evidence that isoforms other than ALDH1A1 
may be secreted into the blood of lung cancer patients, and therefore screening 
sensitivity may be further enhanced by using an isoform-unspecific ALDH test 
without apparently affecting specificity [unpublished results]. Our results showed 
elevated ALDH serum levels can be detected in the vast majority of patients with 
early and advanced stage disease, suggesting that serum ALDH should be evaluated 
as part of a marker panel for noninvasive detection of early lung cancer in a larger 
cohort of patients at risk.
Although identification of proteins is now promising, quantification of proteins 
in complicated mixtures by MS remains challenging, especially in plasma carrying 
a large amount of proteins. Using antibody-based techniques such as ELISA, for 
biomarker measurements, could be hindered by a lack of high-quality antibodies. A 
quantitative approach has evolved, which performs targeted analysis of representa-
tive peptides by multiple reaction monitoring (MRM), and evaluated the potential 
utility of a list of candidate proteins for lung cancer diagnosis.
4.2 Liquid biopsy
Current methods employed for the evaluation of cancer genomes require tissue 
biopsy, either bone marrow biopsy of blood cancer or biopsy of affected nodal/
soft tissue. These procedures are invasive and are limited by being representative of 
only a single site of the disease under evaluation. Thus, single-site tissue biopsy may 
not truly reflect the entire mutational profile of an individual’s disease, and from a 
logistical perspective, it may not be suited to repeat biopsy over short periods of time. 
Liquid biopsy seems to be the most promising and, in contrast to tissue biopsy, is 
noninvasive, can provide a better representation of cancer genetic profile, and can be 
easily repeated [73] (Figure 1). A liquid biopsy is a blood sample of about 10–20 ml 
taken for diagnosis, prognosis, and prediction of a treatment purposes. It is a nonin-
vasive approach to screening and early diagnosis of lung cancer. It consists not only 
of biomarkers but also circulating free DNA (cfDNA) and circulating tumor cells 
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(CTCs). There are two methods for CTC isolation: the indirect CellSearch and the 
direct isolation by size of epithelial tumor cells (ISET) filtration method, which is, to 
date, the most interesting method for early diagnosis and screening of lung cancer 
using CTCs. CTCs can be cytomorphologically characterized before surgery and can 
be detected from asymptomatic patients with stage I lung cancer. Moreover, recent 
studies showed that CTCs can be isolated from patients with high risk of developing 
lung cancer (smokers with chronic obstructive pulmonary disease) without nodules 
detected by CT and that at the follow-up resulted positive for Ade [74, 75]. It was 
also showed that the initial presence of CTCs had a predictive value of 100% of 
developing a secondary lung cancer. As a follow-up to this pilot study performed in 
a single center and on a restricted number of patients, a multicenter study (named 
AIR project) began and has been involving 20 French university hospitals and 600 
patients with chronic obstructive disease, over 55 years who smoked more than 30 
packets per year. This project aims to study patients by means of CTC detection 
through ISET along with CT. Nucleic acids as DNA or RNA fragments can circulate 
in the plasma either freely or present in vesicle, as exosomes. While cfDNA is univer-
sally found in the plasma of healthy people as well as those with benign diseases, it 
has been observed that patients with malignant disease have higher levels of cfDNA 
in their plasma [76]. Among RNA, coding (microRNA) and noncoding RNA can 
circulate. Recent studies have evidenced the more or less complex signature of plasma 
microRNA associated with lung cancer. In particular, it was showed that a signature 
of several plasma microRNA has a predictive value for lung cancer in a high-risk 
population [74]. Although liquid biopsy can permit the monitoring of patients on 
treatment or after treatment for lung cancer, it holds some limits. The major limits 
Figure 1. 
Standard biopsy versus liquid biopsy. The figure illustrates the steps of the standard biopsy, beginning from the 
computed tomography for detecting pulmonary nodules. These are subsequently analyzed by extracting cells or 
tissue fragments, which are examined to determine the presence of the tumor. Liquid biopsy is a 10–20 ml blood 
sample taken for diagnosis, from which CTCs, biomarkers, and cfDNA—including circulating tumoral DNA 
(ctDNA)—are isolated and then analyzed in laboratory.
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for the use of circulating nucleic acids for early lung cancer detection concerns the 
distinction between free nucleic acid of germinal or somatic origin because of the 
lysis of circulating hematological cells and also the low amount detectable in very 
early tumor stages. Moreover, circulating somatic microRNA can be released from 
other diseases associated with lung cancer, such as cardiovascular diseases, inflam-
matory disorders, pulmonary fibrosis, and other associated cancers. Another limit is 
relative to the pre-analytical phase, which is very crucial as the delay between blood 
sampling and the analytical phase should be as short as possible. It should also be the 
same for all the patients involved in the study, for a better comparison of the results, 
and the blood must be conditioned with a buffer that allows excellent conservation of 
the material. Moreover, the low amount of biomarkers, cfDNA or CTCs in the blood 
of patients with a very small tumor or not still visible by thoracic imagery, needs a 
high sensitive technique, which should be able to isolate enough material to conduct 
the analysis. Another problem is represented by the lack of standardization of the dif-
ferent pre-analytical and analytical steps which limit the deployment of liquid biopsy 
in clinical practice for early diagnosis of lung cancer [77–79]. Therefore, it is difficult 
to obtain a specific result if the pre-analytical phase is not standardized among all the 
patients involved in the study and, also, if the clinico-biological information about 
the patient is not known, as other potential comorbidities can emerge.
Other than variants in cfDNA, aberrant DNA methylation of some novel and 
known genes was also investigated in serum of patients with lung cancer by means 
of a quantitative methylation-specific PCR and showed a specificity of 71% [77]. 
Identification of blood-based noninvasive or minimally invasive detection mark-
ers will improve the clinical management of lung cancer. It is noteworthy that this 
simple, reliable, and noninvasive blood test could aid not only the early detection 
of lung cancer but also could be used most effectively to direct imaging modalities 
with low specificity such as CT. Such a test could therefore have a significant impact 
on the long-term survival of these individuals. Moreover, these tests can be helpful 
in monitoring the response to therapy and to identify new actionable mutations.
5. Conclusions
This review summarizes the molecular pathology and the conventional methods 
used for screening of lung cancer, highlighting the advantages and limits of these 
approaches. We also report the recent studies about new circulating biomarkers poten-
tially useful for lung cancer screening. Ideally, a biomarker should have a sensitivity 
and specificity of 100%, a goal that is almost never achieved. One strategy potentially 
increasing both parameters is to combine several biomarkers into a screening marker 
panel. Combined with other noninvasive methods, this may allow for further refine-
ment of lung cancer screening. Liquid biopsy is a 10 ml blood sample taken for diag-
nostic, prognostic, and disease monitoring purposes. It consists not only of biomarkers 
but also circulating cfDNA, RNA, and CTCs. With respect to tissue biopsy, it permits 
to have a better representation of the whole cancer genetic profile and may be suited 
to repeat biopsy over short periods of time. Compared to imaging modalities such as 
X-rays and CT, liquid biopsy represents a more reliable, less invasive, and less expensive 
method for the detection of lung cancer in populations at risk of developing this disease.
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